Author

Dominic Carroll

OpenAlex ID: A5066741055

Effects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients With ESR1-Mutated, ER+/HER2-, Metastatic Breast Cancer From the ELAINE 1 Study

2024 · Shari B. Goldfarb, Sarah L. Sammons, et al. · Clinical Breast Cancer · 3

Abstract PO2-14-09: Baseline genomic alterations and the activity of lasofoxifene (LAS) plus abemaciclib (Abema) in patients with ER+/HER2- metastatic breast cancer (mBC): the ELAINE 2 study

2024 · Senthil Damodaran, Massimo Cristofanilli, et al. · Cancer Research · 1

Abstract P5-05-04: Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA) from patients with ER+/HER2- metastatic breast cancer (mBC) treated with lasofoxifene or fulvestrant in the ELAINE 1 study

2023 · Matthew P. Goetz, Einav Gal-Yam, et al. · Cancer Research · 1

Abstract PO5-12-06: Minimization of treatment toxicity/side effects and their impact on quality of life (QoL) in patients (pts) with ER+/HER2- metastatic breast cancer (mBC)

2024 · Sarah Sammons, Jane Meisel, et al. · Cancer Research

Abstract PO3-12-05: Patient (pt)-provider communication challenges about side effects/toxicities from metastatic breast cancer (mBC) treatments

2024 · Sarah Sammons, Jane Meisel, et al. · Cancer Research

Abstract P5-05-02: Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA) from patients with ER+/HER2- metastatic breast cancer (mBC) treated with lasofoxifene plus abemaciclib in the ELAINE 2 study

2023 · Senthil Damodaran, Halle Moore, et al. · Cancer Research

Abstract P6-09-01: Treatment goals and quality of life (QOL) in a survey of patients with ER+/HER2- metastatic breast cancer (mBC)

2023 · Sarah L. Sammons, Jane Meisel, et al. · Cancer Research

Abstract P6-09-02: Knowledge of tumor/blood genomic testing (NGS) and ESR1 mutations in a survey of patients with ER+/HER2- metastatic breast cancer (mBC)

2023 · Jane Meisel, Sarah L. Sammons, et al. · Cancer Research

Works count: 8

Citation count: 5

H-index: 1

I10-index: